Dear Editor,
In intensive care settings, augmented renal clearance (ARC) is recognized as a leading cause of subtherapeutic antibiotic exposure, and piperacillintazobactam (PTZ) has been the most frequently studied antibiotic in this context [1] [2] [3] [4] [5] (Table 1) . We, like others, previously suggested that higher than licensed dosing regimens should be necessary for empirical treatment in patients with ARC [4, 5] . We thus aimed to determine the efficacy and tolerability of such a strategy.
For this purpose, we performed a retrospective analysis of our local database over a 10-month period (February to November 2018). Ethical approval confirmed the observational design of the study (IRB number: CERAR 00010254-2018-074). Over the study period, every patient with a 24-h measured creatinine clearance (CL Cr ) ≥ 150 mL/min received increased dosing regimens of PTZ (20/2.5 g daily after a loading dose of 4/0.5 g over 60 min) [4] . Subsequent dose adjustments were guided by therapeutic drug monitoring performed between 24 and 72 h of antimicrobial therapy. As previously described, observed concentrations were corrected for protein binding (30% for piperacillin) to estimate unbound fraction [1] .
As MIC data are often not available to the clinician prescribing an empirical antimicrobial regimen, piperacillin underdosing was defined by an unbound concentration under 16 mg/L, representing the highest MIC for Pseudomonas as per the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [4] . Empirical underdosing for tazobactam was defined by an unbound concentration under 2 mg/L, representing the highest MIC for high-level β-lactamase-producing strains [4] . Excessive dosing was defined as a free drug concentration above 150 mg/L [4] . The final dataset consisted of 36 PTZ samples collected from 35 patients. The main characteristics and outcomes of these patients are resumed in Table 2 . Except for one tazobactam sample, all samples were in the therapeutic range (Fig. 1) . No patient experienced excessive dosing above the supposed toxic cutoff ≥ 150 mg/L. Three of them (9%) experienced therapeutic failure or relapse [4] , all related to secondary acquisition of antimicrobial resistance.
When targeting a theoretical MIC at the upper limit of the susceptibility range, higher than licensed doses of PTZ allowed achieving the pharmacodynamic target in all patients with CL Cr ≥ 150 mL/min, without excessive dosing. Further studies are warranted to confirm if such a strategy improves the rate of therapeutic success. 
